Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells

Proteasome inhibition is an attractive approach for anticancer therapy. Doxorubicin (DOX) is widely used for treatment in a number of cancers including breast cancer; however, the development of DOX resistance largely limits its clinical application. One of the possible mechanisms of DOX-resistance...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Shi, Yonghua, Yu, Yang, Wang, Zhenyu, Wang, Hao, Bieerkehazhi, Shayahati, Zhao, Yanling, Suzuk, Lale, Zhang, Hong
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342008/
https://ncbi.nlm.nih.gov/pubmed/27655642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12048
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares